• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics Emergency Classics

The EINSTEIN-PE trial: Rivaroxaban to treat pulmonary embolism [Classics Series]

byEvan ChenandAndrew Cheung, MD MBA
February 25, 2014
in Emergency Classics, General Medicine Classics, The Classics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

Image: PD

1. Rivaroxaban, an oral factor Xa inhibitor, was non-inferior to standard anticoagulation therapy (i.e. low-molecular weight heparin and a vitamin K antagonist) in the prevention of recurrent thromboembolism following a pulmonary embolism.

2. The rate of major bleeding was significantly lower with rivaroxaban than with standard anticoagulant therapy.

Original Date of Publication: April 5, 2012

Study Rundown: For many years, standard therapy for pulmonary embolism (PE) has consisted of low-molecular weight heparin (LMWH) followed by a vitamin K antagonist (VKA), such as warfarin. Although effective, treatment with warfarin requires frequent blood tests and is thus burdensome for patients. In summary, the EINSTEIN-PE study demonstrated that rivaroxaban, an oral factor Xa inhibitor, can be administered without laboratory monitoring in the prevention of recurrent thromboembolism following an acute PE. Specifically, treatment with rivaroxaban alone was non-inferior to standard therapy in preventing recurrent thromboembolism (HR 1.12; 95%CI 0.75-1.68). Rivaroxaban use was also linked with significantly fewer major bleeding events when compared with standard therapy.

A major limitation of the EINSTEIN-PE trial was its open-label design, as this increases the risk of bias. Notably, 5% of patients participating in the study had cancer. Previous studies, including the CLOT trial, have helped establish guidelines recommending the use of LMWH in treating thromboembolism in the context of malignancy, and this recommendation has not changed in light of the findings of the EINSTEIN-PE trial. The study was funded by Bayer HealthCare and Janssen Pharmaceuticals.

Please click to read study in NEJM

RELATED REPORTS

Venous thromboembolism rates in hospitalized children continue to rise

#VisualAbstract: Rivaroxaban prophylaxis improves clinical outcomes in high-risk patients hospitalized with COVID-19

Rivaroxaban prophylaxis improves clinical outcomes in high-risk patients hospitalized with COVID-19

In-Depth [randomized, controlled study]: Originally published in 2012, the EINSTEIN-PE trial was a randomized, open-label, non-inferiority trial involving 4,832 patients.  Eligible patients were those who had an acute, symptomatic PE with or without symptomatic deep-vein thrombosis (DVT). Patients were randomized to receive rivaroxaban, or standard therapy consisting of enoxaparin with either warfarin or acenocoumarol. The primary efficacy outcome was recurrent venous thromboembolism (i.e., PE and/or DVT), and the primary safety outcome was clinically relevant nonmajor bleeding or major bleeding (defined as bleeding in critical sites). Rivaroxaban was non-inferior to standard therapy in preventing recurrent venous thromboembolism post-PE (HR 1.12; 95%CI 0.75-1.68). The rate of major bleeding was also lower in the rivaroxaban group, as compared to standard therapy (HR 0.49; 95%CI 0.31-0.79).

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: pulmonary embolismrivaroxaban
Previous Post

Varenicline safe for smoking cessation in patients with stable major depressive disorder

Next Post

Younger women more likely than men to present with acute coronary syndrome without chest pain

RelatedReports

siRNA against antithrombin alleviates symptoms of hemophilia [PreClinical]
Chronic Disease

Venous thromboembolism rates in hospitalized children continue to rise

February 14, 2022
#VisualAbstract: Rivaroxaban prophylaxis improves clinical outcomes in high-risk patients hospitalized with COVID-19
StudyGraphics

#VisualAbstract: Rivaroxaban prophylaxis improves clinical outcomes in high-risk patients hospitalized with COVID-19

January 26, 2022
Most anticoagulants for venous thromboembolism similarly effective
Hematology

Rivaroxaban prophylaxis improves clinical outcomes in high-risk patients hospitalized with COVID-19

January 18, 2022
Quick Take: Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial
Cardiology

Rivaroxaban associated with significantly increased risk of major ischemic or hemorrhagic events versus apixaban in patients with atrial fibrillation

December 22, 2021
Next Post
Patient transfers to trauma centers often unnecessary

Younger women more likely than men to present with acute coronary syndrome without chest pain

The LACTATE trial: Early lactate-guided therapy in intensive care patients [Classics Series]

Less than one-fifth of patients with hypertension worldwide well controlled

Medicaid beneficiaries among most frequent visitors to the emergency department

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • 2 Minute Medicine Rewind May 22nd, 2022
  • #VisualAbstract: Severe actinic keratosis and need for additional treatment are markers for an increased risk of cutaneous squamous cell carcinoma
  • Virtual yoga and meditation intervention may be associated with increased health-related quality of life
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.